Back

Rock inhibitors target SRSF2 leukemia by disrupting cell mitosis and nuclear morphology

Su, M.; Fleisher, T.; Grosheva, I.; Horev, M. B.; Olszewska, M.; Haim, B.; Plotnikov, A.; Carvalho, S.; Moskovitz, Y.; Minden, M.; Chapal-Ilani, N.; Papapetrou, E. P.; Dezorella, N.; Cheng, T.; Kaushansky, N.; Geiger, B.; Shlush, L. I.

2022-02-17 cancer biology
10.1101/2022.02.15.479934 bioRxiv
Show abstract

Spliceosome machinery mutations are common early mutations in myeloid malignancies, however effective targeted therapies against them are still lacking. In the current study, we used an in vitro high-throughput drug screen among four different isogenic cell lines and identified ROCK inhibitors (ROCKi) as selective inhibitors of SRSF2 mutants. ROCKi targeted SRSF2 Mut primary human samples in a xenografts model and were not toxic to mice nor human cells. ROCKi induced mitotic catastrophe through their apparent effects on microtubules and nuclear organization. Transmission electron microscopy revealed that SRSF2 mutations induce deep nuclear indentation and segmentation, driven by microtubule-rich cytoplasmic intrusions, which were exacerbated by ROCKi. The severe nuclear deformation driven by the combination of SRSF2 Mut and ROCKi prevent cells from completing mitosis. These findings shed light on new ways to target SRSF2 and on the role of the microtubule system in SRSF2 Mut cells.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Nature Communications
○ 5641 papers in training set
Top 7%
19.1%
Similar papers in this journal
2
Science Advances
● 1243 papers in training set
Top 3%
7.0%
Similar papers in this journal
3
Cell Reports
○ 1498 papers in training set
Top 5%
6.5%
Similar papers in this journal
4
Leukemia
○ 42 papers in training set
Top 0.2%
6.5%
Similar papers in this journal
5
Communications Biology
○ 993 papers in training set
Top 3%
4.2%
6
eLife
● 5828 papers in training set
Top 29%
4.2%
Similar papers in this journal
7
Scientific Reports
○ 3612 papers in training set
Top 30%
3.3%
50% of probability mass above
8
Blood Advances
● 62 papers in training set
Top 0.5%
3.3%
9
npj Precision Oncology
○ 53 papers in training set
Top 0.5%
2.9%
10
Blood
● 74 papers in training set
Top 0.6%
2.9%
11
Clinical Cancer Research
● 64 papers in training set
Top 0.8%
2.7%
12
Haematologica
● 25 papers in training set
Top 0.4%
2.0%
13
iScience
○ 1154 papers in training set
Top 16%
1.8%
14
Oncogenesis
○ 12 papers in training set
Top 0.1%
1.7%
15
Journal of Hematology & Oncology
○ 10 papers in training set
Top 0.2%
1.4%
16
Cancers
○ 213 papers in training set
Top 4%
1.2%
17
Life Science Alliance
● 285 papers in training set
Top 5%
1.2%
18
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 33%
1.2%
19
Cell Death & Disease
147 papers in training set
Top 3%
1.1%
20
Oncogene
○ 85 papers in training set
Top 1%
1.0%
21
Cancer Discovery
● 66 papers in training set
Top 2%
1.0%
22
Science Translational Medicine
● 127 papers in training set
Top 3%
0.9%
23
Journal of Experimental Medicine
● 119 papers in training set
Top 3%
0.6%
24
Cell
○ 431 papers in training set
Top 11%
0.6%
25
Oncotarget
○ 18 papers in training set
Top 0.5%
0.6%
26
Molecular Cell
○ 350 papers in training set
Top 5%
0.6%
27
EMBO Molecular Medicine
○ 95 papers in training set
Top 3%
0.6%
28
Neuro-Oncology
◐ 36 papers in training set
Top 0.6%
0.6%
29
Blood Cancer Journal
○ 14 papers in training set
Top 0.3%
0.6%
30
The EMBO Journal
○ 309 papers in training set
Top 8%
0.5%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.